Safety & Efficacy of Nuberol Forte® in Pain Management

The management of musculoskeletal pain is complex therefore plethora of treatment options are available include non-pharmacological treatments , complementary therapies, and pharmacological interventions. In order to provide optimal care to patients with musculoskeletal pain and ensure the efficient use of healthcare resources, a comprehensive overview of the available evidence for the most effective treatment options for musculoskeletal pain presentations is essential. In this context, an observational study is planned on the efficacy and safety of analgesic combination (i.e Nuberol Forte®). Nuberol Forte® is a combination of muscle relaxant (Orphanedrine) and an analgesic/antipyretic (Paracetamol/Acetaminophen). There are clear indications that the combination of Orphenadrine with Paracetamol may give increased antinociceptive activity and duration of action over and above the use of Orphenadrine or Paracetamol alone.

Inclusion criteria

• Patient with a clinical history of painful musculoskeletal disorder from last 1 year
• Patient aged ≥18 and ≤70 years inclusive of either sex
• Patient with ability to understand and sign written informed consent form.

Exclusion criteria

• Known hypersensitivity to Nuberol Forte product, the metabolites, or formulation excipients.
• Patients with Glaucoma, prostatic hypertrophy or obstruction at the bladder neck, myasthenia gravis, oesophageal spasm and pyloric or duodenal obstruction.
• Treated with Nuberol Forte to evaluate safety as per approved prescribing information for Nuberol Forte in Pakistan.
• Pregnant (assesed on LMP) or breast feeding women (assessed on interview).